“减肥神药”进入口服时代,礼来登顶“减肥药王”?

华尔街见闻
18 Apr

华尔街分析师普遍认为,GLP-1减肥药领域正在从注射剂型向便捷的口服形式转变,而礼来已经取得了早期领先优势。这场激烈的多年竞争已经有了明显的赢家,至少目前看来,礼来已被市场加冕为GLP-1药物领域的新王者。礼来公司的口服减肥药Orforglipron在三期临床试验中表现出色,可以媲美甚至超越注射型GLP-1药物。市场对礼来的突破性进展反应强烈。4月17日,礼来股价收涨超14%,盘中暴涨16%,创下...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10